IVT mRNA: Unlocking a New Era in Gene Editing and Regenerative Medicine
Regeneron
Biopharmaceutical Manufacturer
Click the blue text
Follow Us
Gene Editing, Cell Regeneration, and Organ Repair: mRNA Technology is Rewriting the Future of Medicine. When it comes to IVT mRNA (in vitro transcribed messenger RNA), the first things that come to mind are COVID-19 vaccines and cancer immunotherapy. This Nobel Prize-winning technology is quietly sparking a revolution across various fields of medicine. Beyond vaccine development, IVT mRNA is advancing at an astonishing pace in applications such as gene editing, regenerative medicine, and disease diagnosis, showing immense potential to transform the medical paradigm. Let’s explore these exciting new directions together!
Gene Editing: The "Molecular Scalpel" of Precision Medicine
CRISPR-Cas9 Gene Editing Technology: IVT mRNA as the Core Driving Component. This high specificity and efficiency enable gene editing to repair disease-causing mutations or modify genes with unprecedented precision, providing a powerful tool for the treatment of genetic disorders.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
CRISPR-Cas9 Genome Editing Therapy[1]
Intellia and Regeneron Jointly Announce Positive Interim Data from Phase I Clinical Study of In Vivo CRISPR-Cas9 Genome Editing Therapy NTLA-2001 for Transthyretin Amyloidosis (ATTR). NTLA-2001 is a novel in vivo gene-editing CRISPR-Cas9 therapy, consisting of a proprietary lipid nanoparticle (LNP) delivery system with liver-targeting properties, carrying a single guide RNA (sgRNA) targeting human TTR and a Streptococcus pyogenes Cas9 mRNA sequence. It aims to silence TTR in hepatocytes through intravenous infusion, reducing the production of both wild-type and mutant TTR after a single administration.[1]Three patients with transthyretin (ATTR) amyloidosis who previously received the lowest dose of NTLA-2001 in a Phase 1 dose-escalation study experienced a median 90% reduction in serum transthyretin (TTR) protein levels after receiving a subsequent 55mg dose of NTLA-2001. According to the press release, this is the first clinical data showing that in vivo CRISPR/Cas9 gene editing therapy can be effectively re-administered, successfully completing the clinical proof of concept.[2]。
Regenerative Medicine: The "Programming Instructions" for Organ Regeneration
The most exciting advancement in the field of regenerative medicine is the use of mRNA technology to enable self-repair of damaged organs.mRNA technology delivers pro-regenerative factors (such as VEGFA, HGF, EGF), encodes bone morphogenetic proteins (BMP-2), and transcription factors, among other mRNA molecules that encode specific functional proteins, guiding the body's own cells to express therapeutic proteins for tissue repair and regeneration.
Delivery of mRNA Encoding Specific Functional Proteins Guides Organ Cell Regeneration in Different Species[3]
Currently, this technology has been applied by multiple research teams for hepatocyte regeneration in animal models such as mice, rats, and cynomolgus monkeys.[4], Bone Repair[5], and even the in vivo generation of CAR-T cells[6], and has made considerable progress.
Future Outlook: From Lab to Clinic
With continuous technological breakthroughs, the application landscape of IVT mRNA is rapidly expanding:
Stem Cell Engineering: Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) via IVT mRNA, without the use of viral vectors, significantly reduces safety risks.
CAR-T Cell Therapy: Transient expression of CAR constructs in T cells using mRNA to enhance treatment safety and controllability.
Protein Replacement Therapy: Provide a brand-new solution for traditionally "undruggable" protein drugs.
Agriculture and Veterinary Fields: Expanding from human medicine to livestock farming, aquaculture, and pet healthcare.
IVT mRNA Technology Is Reshaping the Future Boundaries of Medicine. With the optimization of delivery systems, the refinement of sequence design, and the enhancement of safety, we have good reason to believe that this "master key" technology will unlock unprecedented treatment possibilities in more fields, bringing revolutionary changes to human health!
References:
[1] Julian D, Gillmore,Ed, Gane,Jorg, Taubel et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.[J] .N Engl J Med, 2021, 385: 0.
[2] CanCRISPR be given twice? Small study from Intellia suggests it can. Retrieved June26, 2024 from https://endpts.com/can-crispr-be-given-twice-small-study-from-intellia-suggests-it-can/
[3] Fatima, Rizvi,Yu-Ri, Lee,Ricardo, Diaz-Aragon et al. VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis.[J] .Cell Stem Cell, 2023, 30: 0.
[4] Fatima, Rizvi,Elissa, Everton,Anna R, Smith et al. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA.[J] .Nat Commun, 2021, 12: 0.
[5] Rodolfo E, De La Vega,Martijn, van Griensven,Wen, Zhang et al. Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2.[J] .Sci Adv, 2022, 8: 0.
[6] Theresa L, Hunter,Yanjie, Bao,Yan, Zhang et al. In vivo CAR T cell generation to treat cancer and autoimmune disease.[J] .Science, 2025, 388: 0.
Previous Highlights
"Three Major Application Breakthroughs" in mRNA Lipid Nanoparticle Delivery Technology
saRNA Technology: Multi-Field Applications Leading Medical Innovation
Official Account:
Orange Life
Weekly Sharing of Antibody, Protein & RNA Related Content
Press and hold the QR code to follow the Nearshore CRO Services WeChat Official Account
Share
Like
In View